CN101970418B - 吡嗪衍生物及其作为蛋白激酶抑制剂的用途 - Google Patents

吡嗪衍生物及其作为蛋白激酶抑制剂的用途 Download PDF

Info

Publication number
CN101970418B
CN101970418B CN2009801038291A CN200980103829A CN101970418B CN 101970418 B CN101970418 B CN 101970418B CN 2009801038291 A CN2009801038291 A CN 2009801038291A CN 200980103829 A CN200980103829 A CN 200980103829A CN 101970418 B CN101970418 B CN 101970418B
Authority
CN
China
Prior art keywords
indol
acid
amino
pyrazin
pyridin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2009801038291A
Other languages
English (en)
Chinese (zh)
Other versions
CN101970418A (zh
Inventor
安尼卡·珍玛姆·詹森
弗雷德里克·莱曼
比约恩·M··尼尔松
埃里克·努德林德
文德拉·帕罗
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Akinion Pharmaceuticals AB
Original Assignee
Akinion Pharmaceuticals AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akinion Pharmaceuticals AB filed Critical Akinion Pharmaceuticals AB
Publication of CN101970418A publication Critical patent/CN101970418A/zh
Application granted granted Critical
Publication of CN101970418B publication Critical patent/CN101970418B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN2009801038291A 2008-02-01 2009-01-28 吡嗪衍生物及其作为蛋白激酶抑制剂的用途 Expired - Fee Related CN101970418B (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
SE0800250-3 2008-02-01
SE0800250 2008-02-01
US12303908P 2008-04-04 2008-04-04
US61/123,039 2008-04-04
SE0801185 2008-05-21
SE0801185-0 2008-05-21
PCT/EP2009/050931 WO2009095399A2 (en) 2008-02-01 2009-01-28 Pyrazine derivatives and their use as protein kinase inhbitors

Publications (2)

Publication Number Publication Date
CN101970418A CN101970418A (zh) 2011-02-09
CN101970418B true CN101970418B (zh) 2013-07-03

Family

ID=40527384

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2009801038291A Expired - Fee Related CN101970418B (zh) 2008-02-01 2009-01-28 吡嗪衍生物及其作为蛋白激酶抑制剂的用途

Country Status (18)

Country Link
US (2) US8436171B2 (enExample)
EP (2) EP2252597B1 (enExample)
JP (2) JP5562256B2 (enExample)
KR (1) KR101599082B1 (enExample)
CN (1) CN101970418B (enExample)
AU (1) AU2009209633C1 (enExample)
BR (1) BRPI0907453A2 (enExample)
CA (1) CA2713553A1 (enExample)
CY (1) CY1115400T1 (enExample)
DK (1) DK2252597T3 (enExample)
ES (1) ES2459297T3 (enExample)
HR (1) HRP20140547T1 (enExample)
MX (1) MX2010007973A (enExample)
PL (1) PL2252597T3 (enExample)
PT (1) PT2252597E (enExample)
RU (1) RU2493152C2 (enExample)
SI (1) SI2252597T1 (enExample)
WO (1) WO2009095399A2 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2252597T1 (sl) * 2008-02-01 2014-07-31 Akinion Pharmaceuticals Ab Derivati pirazina in njihova uporaba kot inhibitorji protein kinaze
WO2011083124A1 (en) 2010-01-05 2011-07-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Flt3 receptor antagonists for the treatment or the prevention of pain disorders
WO2013089636A1 (en) * 2011-12-15 2013-06-20 Akinion Pharmaceuticals Ab Processes for manufacturing of a kinase inhibitor
AU2013232208B2 (en) * 2012-03-14 2017-04-27 Indiana University Research And Technology Corporation Compounds and methods for treating leukemia
AU2013250378B2 (en) * 2012-04-17 2016-01-14 Fujifilm Corporation Nitrogen-containing heterocyclic compound or salt thereof
UY34807A (es) * 2012-05-16 2013-12-31 Novartis Ag Derivados monocíclicos de heteroarilcicloalquil- diamina
DK3059227T3 (da) 2013-10-16 2019-08-26 Fujifilm Corp Salt af en nitrogen-holdig heterocyklisk forbindelse eller krystal deraf, farmaceutisk sammensætning og flt3-hæmmer
US10065937B2 (en) 2014-07-31 2018-09-04 Inserm (Institut National De La Sante Et De La Recherche Medicale) FLT3 receptor antagonists
JP6257782B2 (ja) 2014-08-22 2018-01-10 富士フイルム株式会社 Ｆｌｔ３変異陽性癌を処置するための医薬組成物、変異型ｆｌｔ３阻害剤およびそれらの応用
CN105985322A (zh) * 2015-03-03 2016-10-05 苏州翔实医药发展有限公司 氨基吡嗪化合物及其用途
JP6412471B2 (ja) 2015-07-15 2018-10-24 富士フイルム株式会社 含窒素複素環化合物の製造方法およびその中間体
EP3254698A1 (en) 2016-06-08 2017-12-13 Universite De Montpellier Flt3 receptor inhibitor at low dosage for the treatment of neuropathic pain
WO2018211018A1 (en) 2017-05-17 2018-11-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Flt3 inhibitors for improving pain treatments by opioids
WO2019018584A1 (en) 2017-07-18 2019-01-24 GiraFpharma LLC HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS
WO2019057649A1 (en) 2017-09-19 2019-03-28 INSERM (Institut National de la Santé et de la Recherche Médicale) METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA
CN110483366B (zh) * 2018-05-14 2022-09-16 中国医学科学院药物研究所 吲哚类化合物及其制备方法、药物组合物和用途
CN113939291A (zh) 2019-01-18 2022-01-14 诺维逊生物股份有限公司 1,8-萘啶酮化合物及其用途
WO2020150677A1 (en) * 2019-01-18 2020-07-23 Nuvation Bio Inc. Heterocyclic compounds as adenosine antagonists
MX2021008650A (es) 2019-01-18 2021-11-03 Nuvation Bio Inc Compuestos heterociclicos como antagonistas de adenosina.
KR20210142154A (ko) 2019-03-21 2021-11-24 옹쎄오 암 치료를 위한 키나제 억제제와 조합된 dbait 분자
JP2023500906A (ja) 2019-11-08 2023-01-11 インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） キナーゼ阻害剤に対する獲得抵抗性を有するがんの処置方法
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
CN112574192B (zh) * 2020-12-24 2021-10-01 烟台大学 氨基酸衍生联噻唑-色胺类抗癌化合物和应用
KR20250075303A (ko) * 2023-11-21 2025-05-28 (주)신테카바이오 크레놀라닙 또는 이의 약학적으로 허용 가능한 염을 포함하는 건선의 예방 또는 치료용 조성물
KR20250075302A (ko) * 2023-11-21 2025-05-28 (주)신테카바이오 크레놀라닙 또는 이의 약학적으로 허용 가능한 염을 포함하는 아토피 피부염의 예방 또는 치료용 조성물

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2400101A (en) * 2003-03-28 2004-10-06 Biofocus Discovery Ltd Compounds capable of binding to the active site of protein kinases
WO2005058876A1 (en) * 2003-12-16 2005-06-30 Gpc Biotech Ag Pyrazine derivatives as effective compounds against infectious diseases

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW225528B (enExample) * 1992-04-03 1994-06-21 Ciba Geigy Ag
RU2340611C2 (ru) * 2000-09-15 2008-12-10 Вертекс Фармасьютикалз Инкорпорейтед Производные пиразола, используемые в качестве ингибиторов протеинкиназы
US20040102455A1 (en) * 2001-01-30 2004-05-27 Burns Christopher John Method of inhibiting kinases
CN100558715C (zh) * 2002-05-23 2009-11-11 西托匹亚有限公司 蛋白激酶抑制剂
AUPS251502A0 (en) * 2002-05-23 2002-06-13 Cytopia Pty Ltd Protein kinase inhibitors
US7563748B2 (en) 2003-06-23 2009-07-21 Cognis Ip Management Gmbh Alcohol alkoxylate carriers for pesticide active ingredients
JP2007533635A (ja) * 2003-09-30 2007-11-22 アムジエン・インコーポレーテツド バニロイド受容体リガンドおよび治療おけるこれらの使用
EP1742935B1 (en) * 2004-04-13 2010-02-24 Icagen, Inc. Polycyclic pyrazines as potassium ion channel modulators
WO2006000020A1 (en) 2004-06-29 2006-01-05 European Nickel Plc Improved leaching of base metals
GB0428082D0 (en) * 2004-12-22 2005-01-26 Welcome Trust The Ltd Therapeutic compounds
TW200801513A (en) 2006-06-29 2008-01-01 Fermiscan Australia Pty Ltd Improved process
ATE517868T1 (de) * 2006-08-16 2011-08-15 Boehringer Ingelheim Int Pyrazinverbindungen, ihre verwendung und herstellungsverfahren
WO2008058341A1 (en) * 2006-11-15 2008-05-22 Cytopia Research Pty Ltd Inhibitors of kinase activity
SI2252597T1 (sl) * 2008-02-01 2014-07-31 Akinion Pharmaceuticals Ab Derivati pirazina in njihova uporaba kot inhibitorji protein kinaze

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2400101A (en) * 2003-03-28 2004-10-06 Biofocus Discovery Ltd Compounds capable of binding to the active site of protein kinases
WO2005058876A1 (en) * 2003-12-16 2005-06-30 Gpc Biotech Ag Pyrazine derivatives as effective compounds against infectious diseases

Also Published As

Publication number Publication date
WO2009095399A3 (en) 2009-10-01
BRPI0907453A2 (pt) 2015-07-14
EP2252597B1 (en) 2014-03-19
AU2009209633B2 (en) 2013-07-18
JP2011510948A (ja) 2011-04-07
HRP20140547T1 (hr) 2014-07-18
MX2010007973A (es) 2010-11-09
EP2671876A2 (en) 2013-12-11
KR101599082B1 (ko) 2016-03-02
ES2459297T3 (es) 2014-05-08
JP2014148522A (ja) 2014-08-21
HK1149268A1 (en) 2011-09-30
RU2010136653A (ru) 2012-03-10
KR20100116599A (ko) 2010-11-01
DK2252597T3 (da) 2014-04-28
EP2252597A2 (en) 2010-11-24
RU2493152C2 (ru) 2013-09-20
AU2009209633A1 (en) 2009-08-06
CA2713553A1 (en) 2009-08-06
WO2009095399A2 (en) 2009-08-06
CY1115400T1 (el) 2017-01-04
PT2252597E (pt) 2014-04-30
US20110098310A1 (en) 2011-04-28
EP2671876A3 (en) 2014-02-05
SI2252597T1 (sl) 2014-07-31
US8436171B2 (en) 2013-05-07
US20130203774A1 (en) 2013-08-08
CN101970418A (zh) 2011-02-09
JP5562256B2 (ja) 2014-07-30
AU2009209633C1 (en) 2014-01-23
PL2252597T3 (pl) 2014-09-30

Similar Documents

Publication Publication Date Title
CN101970418B (zh) 吡嗪衍生物及其作为蛋白激酶抑制剂的用途
CN113646307B (zh) 具有蛋白激酶抑制活性的吡啶并[3,4-d]嘧啶-8-酮衍生物及其药物组合物
CN106946796B (zh) 用作激酶活性调节剂的氨基嘧啶衍生物
CN104080774B (zh) 吡嗪甲酰胺化合物
AU778533B2 (en) 5-cyano-2-aminopyrimidine derivatives
CN110891953B (zh) 吡咯并三嗪类衍生物、其制备方法及其用途
CN102015660A (zh) 2-氨基喹唑啉衍生物
HK1149268B (en) Pyrazine derivatives and their use as protein kinase inhbitors
HK1188448A (en) Pyrazine derivatives and their use as protein kinase inhbitors
RU2780168C1 (ru) Новое производное пиридо [3,4-d] пиримидин-8-она, обладающее ингибирующей протеинкиназы активностью, и фармацевтическая композиция для предупреждения, облегчения или лечения рака, содержащее указанное выше
KR20200142245A (ko) 신규한 인다졸 유도체 화합물 및 이를 포함하는 암의 예방, 개선 또는 치료용 약학 조성물
HK40056366B (zh) 具有蛋白激酶抑制活性的吡啶并[3，4-d]嘧啶-8-酮衍生物及其药物组合物
HK40056366A (en) Pyrido[3,4-d]pyrimidin-8-one derivative having protein kinase inhibitory activity, and pharmaceutical composition thereof
HK1198168B (zh) 用作激酶活性调节剂的氨基嘧啶衍生物
HK1240220A1 (en) Aminopyrimidine derivatives for use as modulators of kinase activity
HK1203491B (en) Pyrazine carboxamide compound

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1149268

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1149268

Country of ref document: HK

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20130703

Termination date: 20200128

CF01 Termination of patent right due to non-payment of annual fee